Search - tctmd.com

Displaying 441 - 460 of 892

Sort: Relevancy | Date

Presentation TCT 2019

PFO Closure for Primary Prevention: The Debate Has Started — A Case Example and a Clinical Trial Proposal

Presenter: Fabian Nietlispach

September 27, 2019

Presentation TCT 2019

PFO Closure for Stroke: The Debate Is Over

Presenter: Stephen Brecker

September 27, 2019

Presentation TCT 2019

Novel Approaches in Diabetic Patients After PCI: Role of SGLT2 Inhibitors and Potent Antiplatelet Therapy (THEMIS)

Presenter: Marc Bonaca

September 26, 2019

Presentation TCT 2019

Tackling Inflammation: Novel Targets

Presenter: Wolfgang Koenig

September 26, 2019

Presentation TCT 2019

LP(a): Not So Little Anymore

Presenter: Roberta Rossini

September 26, 2019

Presentation TCT 2019

Don’t Forget About Your HDL: The AEGIS Program

Presenter: C. Michael Gibson

September 26, 2019

Presentation TCT 2019

Role of PCSK9 Inhibitors Post-PCI and ACS

Presenter: Marc Bonaca

September 26, 2019

Presentation TCT 2019

Loading Dose Statin Prior PCI: Is There a Role For It?

Presenter: Renato Lopes

September 26, 2019

News Conference News HFSA 2019

Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention

L.A. McKeown

September 24, 2019

News Conference News ESC 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

Todd Neale

September 10, 2019

News Conference News ESC 2019

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Yael L. Maxwell

September 10, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

News Conference News ESC 2019

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

Caitlin E. Cox

September 06, 2019

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

News Conference News ESC 2019

Stopped Early, DAPA Offers Insight on ICD Timing After STEMI

Shelley Wood

September 04, 2019

News Conference News ESC 2019

Long-term Secondary Prevention Post-CABG Important Yet Lacking: SWEDEHEART

Yael L. Maxwell

September 04, 2019

News Conference News ESC 2019

Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4

Michael O'Riordan

September 02, 2019

News Conference News ESC 2019

Increasing Oral Anticoagulation Use Tied to Less Ischemic Stroke in A-fib Patients in Italy

Todd Neale

August 31, 2019

News Conference News ESC 2019

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

Shelley Wood

August 31, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

Advertisement

PFO Closure for Primary Prevention: The Debate Has Started — A Case Example and a Clinical Trial Proposal

PFO Closure for Stroke: The Debate Is Over

Novel Approaches in Diabetic Patients After PCI: Role of SGLT2 Inhibitors and Potent Antiplatelet Therapy (THEMIS)

Tackling Inflammation: Novel Targets

LP(a): Not So Little Anymore

Don’t Forget About Your HDL: The AEGIS Program

Role of PCSK9 Inhibitors Post-PCI and ACS

Loading Dose Statin Prior PCI: Is There a Role For It?

Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Stopped Early, DAPA Offers Insight on ICD Timing After STEMI

Long-term Secondary Prevention Post-CABG Important Yet Lacking: SWEDEHEART

Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4

Increasing Oral Anticoagulation Use Tied to Less Ischemic Stroke in A-fib Patients in Italy

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content